Aromatase and its inhibitors: Significance for breast cancer therapy

Recent Progress in Hormone Research

Volumn 57, Issue , 2002, Pages 317-338

  Simpson, Evan R ^a   Dowsett, Mitch ^b  

^a MONASH MEDICAL CENTRE   (Australia)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; AROMATASE; AROMATASE INHIBITOR; ESTROGEN; EXEMESTANE; FADROZOLE; FORMESTANE; LETROZOLE; TAMOXIFEN; VOROZOLE;

AGING; ARTICLE; BINDING AFFINITY; BONE ATROPHY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER PREVENTION; COGNITIVE DEFECT; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME INHIBITION; ESTROGEN SYNTHESIS; FEMALE; HUMAN; POSTMENOPAUSE; STRUCTURE ACTIVITY RELATION; TISSUE DISTRIBUTION;

ANIMALS; AROMATASE; AROMATASE INHIBITORS; BREAST NEOPLASMS; ENZYME INHIBITORS; ESTROGENS; FEMALE; HUMANS;

EID: 0036374410     PISSN: 00799963     EISSN: None     Source Type: Journal    
DOI: 10.1210/rp.57.1.317     Document Type: Article

References (80)

1. Use of alternative promoters to express the aromatase cytochrome P450 (CYP19) gene in breast adipose tissues of cancer-free and breast cancer patients
2. Double-blind, randomised, multicentre endocrine trial comparing two letrozole doses, in postmenopausal breast cancer patients
3. Vorozole versus aminoglutethimide in the treatment of postmenopausal breast cancer relapsing after tamoxifen
4. Intracellular aromatase and its relevance to the pharmacological efficacy of aromatase inhibitors
5. Comparative clinical pharmacology and pharmacokinetic interactions of aromatase inhibitors
6. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: Results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study
7. 1. Estrogen antagonists. Aromatase inhibitors, their pharmacology and application
8. Inactivation of aromatase in vitro by 4-hydroxy-4androstene-3,17-dione and 4-acetoxy-4-androstene-3,17-dione and sustained effects in vivo
9. Correlation of aromatase and cyclo-oxygenase gene expression in human breast cancer specimens
10. Advances in aromatase inhibition: Clinical efficacy and tolerability in the treatment of breast cancer
11. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: Results of overview analysis of two phase III trials
12. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation
13. Molecular origin of cancer: Catechol estrogen-3,4-quinone as endogenous tumor initiators
14. Antitumoral and endocrine effects of (+)-vorozole in rats bearing dimethylbenzanthracene-induced mammary tumors
15. Inhibition of breast cancer tissue aromatase activity and estrogen concentrations by the third-generation aromatase inhibitor vorozole
16. Lessons from the use of aromatase inhibitors in the neoadjuvant setting
17. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: Double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate
18. Use of the aromatase inhibitor 4-hydroxyandrostenedione in postmenopausal breast cancer: Optimization of therapeutic dose and route
19. Tamoxifen for early breast cancer: An overview of the randomised trials
20. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: Evidence from a phase III randomized trial
21. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial
22. Tamoxifen for prevention of breasst cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
23. In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients
24. Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized cross-over-designed study
25. Letrozole, a new oral aromatase inhibitor: Randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutehimide in postmenopausal women with advanced breast cancer
26. Aromatase inhibitors
27. A three-dimensional model of aromatase cytochrome P450
28. P450s: Structural similarities and functional differences
29. Prevention of spontaneous tumours in female rats by fadrozole hydrochloride, an aromatase inhibitor
30. Tissue-specific expression of the human aromatase cytochrome P450 gene by alternative use of multiple exons 1 and promoters, and switching of tissue-specific exons 1 in carcinogenesis
31. Structural characterization of the human estrogen synthetase (aromatase gene)
32. Comparison of the systemic and intratumoural effects of tamoxifen and the aromatase inhibitor vorozole in postmenopausal patients with breast cancer
33. Chemoprevention of breast cancer in rats by celecoxib, a cycloxygenase 2 inhibitor
34. Non-steroidal anti-inflammatory drugs and breast cancer
35. Endogenous and exogenous endocrine factors
36. Measurement of aromatisation by a urine technique suitable for the evaluation of aromatase inhibitors in vivo
37. Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women: Three-year data from 2 double-blind, randomized, placebo-controlled trials
38. The influence of intramuscular 4-hydroxyandrostenedione on peripheral aromatisation in breast cancer patients
39. Binding characteristics of seven inhibitors of human aromatase: A site-directed mutagenesis study
40. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: Results of a phase III randomized double-blind trial
41. Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells
42. Physiological changes in dehydroepiandrosterone are not reflected by serum levels of active androgens and estrogen but of their metabolites: Intracrinology
43. Marked decline in serum concentrations of adrenal C19 sex steroid precursor
44. DHEA and the intracrine formation of androgens and estrogens in peripheral target tissues: Its role during aging
45. An in vivo model of intratumoural aromatase using aromatase-transfected MCF7 human breast cancer cells
46. Clinico-pharmacological aspects of different hormone treatments
47. The influence of CGS 16949A on peripheral aromatisation in breast cancer patients
48. The effects of aromatase inhibitors and antiestrogens in the nude mouse model
49. The influence of aminoglutethimide and its analogue rogletimide on peripheral aromatisation in breast cancer
50. Tissue-specific and hormonally controlled alternative promoters regulate aromatase cytochrome P450 gene expression in human adipose tissue
51. Tissue-specific promoters regulate aromatase cytochrome P450 gene expression in human ovary and fetal tissues
52. Structural analysis of the gene encoding human aromatase cytochrome P-450, the enzyme responsible for estrogen biosynthesis
53. Biology of aromatase inhibitors: Pharmacology/endocrinology within the breast
54. The importance of local synthesis of estrogen within the breast
55. Use of an aromatase inhibitor for induction of ovulation in patients with an inadequate response to clomiphene citrate
56. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: Results of a phase III study of the International Letrozole Breast Cancer Group
57. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: Results of a North American multicenter randomized trial
58. P450 superfamily: Update on new sequences, gene mapping, accession numbers and nomenclature
59. Concentrations of estrone, estradiol, and estrone sulfate and evaluation of sulfatase and aromatase activities in pre and postmenopausal breast cancer patients
60. Comparison of the selective aromatase inhibitor formestane with tamoxifen as first-line hormonal therapy in postmenopausal women with advanced breast cancer
61. A pilot trial to evaluate the acute toxicity and feasibility of tamoxifen for prevention of breast cancer
62. In situ oestrone synthesis in normal breast and breast tumour tissues: Effect of treatment with 4-hydroxyandrostenedione
63. Aminoglutehimide inhibits extraglandular estrogen production in postmenopausal women with breast carcinoma
64. Aromatase in human bone tissue
65. Prostaglandin E2 production and metabolism in human breast cancer cells and breast fibroblasts. Regulation by inflammatory mediators
66. A highly complex organization of the regulatory region of the human CYP19 (aromatase) gene revealed by the human genome project
67. Effect of estrogen deprivation on the reproductive physiology of male and female primates
68. Aromatase expression of human osteoblast-like cells
69. The role of local estrogen biosynthesis in males and females
70. Aromatase expression in health and disease
71. Low-dose aminoglutehimide in treatment of advanced breast cancer
72. Endogenous estrogen and postmenopausal breast cancer: Quantitative review
73. Utilization of oxygen and reduced nicotinamide adeninedinucleotide phosphate by human placental microsomes during aromatization of androstenedione
74. First-line fadrozole HCI (CGS 16949A) versus tamoxifen in postmenopausal women with advanced breast cancer. Prospective randomised trial of the Swiss Group for Clinical Cancer Research SAKK 20/88
75. Structural and functional characterization of human aromatase
76. A pivotal double-blind trial in Japan of an aromatase inhibitor Letrozole (third generation) vs. its predecessor fadrozole hydrochloride (second generation)
77. Inhibition of the in vivo conversion of androstenedione to estrone by the aromatase inhibitor vorozole in healthy postmenopausal women
78. Stimulation of aromatase P450 promoter (II) activity in endometriosis and its inhibition in endometrium are regulated by competitive binding of steroidogenic factor-1 and chicken ovalbumin upstream promoter transcription factor to the same cis-acting element
79. Estrogen biosynthesis proximal to a breast tumor is stimulated by PGE2 via cyclic AMP, leading to activation of promoter II of the CYP19 (aromatase) gene
80. Gene regulation studies of aromatase expression in breast cancer and adipose stromal cells